194 related articles for article (PubMed ID: 35572591)
1. Aberrant HSP90 Expression in Lymphocytes and HSP90 Response to Anti-PD-1 Therapy in Lymphoma Patients.
Albakova Z; Mangasarova Y; Albakov A; Nikulina E; Kravchenko S; Sapozhnikov A
Front Immunol; 2022; 13():893137. PubMed ID: 35572591
[TBL] [Abstract][Full Text] [Related]
2. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
[TBL] [Abstract][Full Text] [Related]
3. Checkpoint Inhibitors Hodgkin Lymphoma and Non-Hodgkin Lymphoma.
Hu B; Jacobs R; Ghosh N
Curr Hematol Malig Rep; 2018 Dec; 13(6):543-554. PubMed ID: 30338457
[TBL] [Abstract][Full Text] [Related]
4. Heat shock protein 90 inhibitor BIIB021 (CNF2024) depletes NF-kappaB and sensitizes Hodgkin's lymphoma cells for natural killer cell-mediated cytotoxicity.
Böll B; Eltaib F; Reiners KS; von Tresckow B; Tawadros S; Simhadri VR; Burrows FJ; Lundgren K; Hansen HP; Engert A; von Strandmann EP
Clin Cancer Res; 2009 Aug; 15(16):5108-16. PubMed ID: 19671844
[TBL] [Abstract][Full Text] [Related]
5. Primary and acquired resistance mechanisms to immune checkpoint inhibition in Hodgkin lymphoma.
Veldman J; Visser L; Berg AVD; Diepstra A
Cancer Treat Rev; 2020 Jan; 82():101931. PubMed ID: 31756590
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
[TBL] [Abstract][Full Text] [Related]
7. Immune phenotypes and checkpoint molecule expression of clonally expanded lymph node-infiltrating T cells in classical Hodgkin lymphoma.
Ballhausen A; Ben Hamza A; Welters C; Dietze K; Bullinger L; Rahn HP; Hartmann S; Hansmann ML; Hansmann L
Cancer Immunol Immunother; 2023 Feb; 72(2):515-521. PubMed ID: 35947165
[TBL] [Abstract][Full Text] [Related]
8. An HPK1 inhibitor enhanced the tumour response to anti-PD-1 immunotherapy in non-Hodgkin's lymphoma.
Yang L; Zhao Q; Chen T; Liu W; Qiu X; Chen J; Huang S; Huang R; Dong L
Clin Exp Med; 2023 Nov; 23(7):3767-3780. PubMed ID: 37106265
[TBL] [Abstract][Full Text] [Related]
9. PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma.
Tobin JWD; Bednarska K; Campbell A; Keane C
Cells; 2021 May; 10(5):. PubMed ID: 34068762
[TBL] [Abstract][Full Text] [Related]
10. Steroid resistance in COPD is associated with impaired molecular chaperone Hsp90 expression by pro-inflammatory lymphocytes.
Hodge G; Roscioli E; Jersmann H; Tran HB; Holmes M; Reynolds PN; Hodge S
Respir Res; 2016 Oct; 17(1):135. PubMed ID: 27769261
[TBL] [Abstract][Full Text] [Related]
11. Checkpoint Inhibitors and Other Immune Therapies for Hodgkin and Non-Hodgkin Lymphoma.
Matsuki E; Younes A
Curr Treat Options Oncol; 2016 Jun; 17(6):31. PubMed ID: 27193488
[TBL] [Abstract][Full Text] [Related]
12. Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma.
Apostolidis J; Sayyed A; Darweesh M; Kaloyannidis P; Al Hashmi H
J Immunol Res; 2020; 2020():9350272. PubMed ID: 33178841
[TBL] [Abstract][Full Text] [Related]
13. Expression of heat-shock protein-90 in non-Hodgkin's lymphomas.
Valbuena JR; Rassidakis GZ; Lin P; Atwell C; Georgakis GV; Younes A; Jones D; Medeiros LJ
Mod Pathol; 2005 Oct; 18(10):1343-9. PubMed ID: 16056252
[TBL] [Abstract][Full Text] [Related]
14. Hsp90β inhibition upregulates interferon response and enhances immune checkpoint blockade therapy in murine tumors.
Rahmy S; Mishra SJ; Murphy S; Blagg BSJ; Lu X
Front Immunol; 2022; 13():1005045. PubMed ID: 36341371
[TBL] [Abstract][Full Text] [Related]
15. Immunotherapy of Hodgkin Lymphoma: Mobilizing the Patient's Immune Response.
Ansell SM
Cancer J; 2018; 24(5):249-253. PubMed ID: 30247261
[TBL] [Abstract][Full Text] [Related]
16. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.
Goodman A; Patel SP; Kurzrock R
Nat Rev Clin Oncol; 2017 Apr; 14(4):203-220. PubMed ID: 27805626
[TBL] [Abstract][Full Text] [Related]
17. Immune Reconstitution following High-Dose Chemotherapy and Autologous Stem Cell Transplantation with or without Pembrolizumab Maintenance Therapy in Patients with Lymphoma.
Merryman RW; Redd R; Jeter E; Wong JL; McHugh K; Reynolds C; Nazzaro M; Varden A; Brown JR; Crombie JL; Davids MS; Fisher DC; Jacobsen E; Jacobson CA; Kim AI; LaCasce AS; Ng SY; Odejide OO; Parry EM; Dahi PB; Nieto Y; Joyce RM; Chen YB; Herrera AF; Armand P; Ritz J
Transplant Cell Ther; 2022 Jan; 28(1):32.e1-32.e10. PubMed ID: 34670169
[TBL] [Abstract][Full Text] [Related]
18. HSP90 Inhibition Enhances Cancer Immunotherapy by Modulating the Surface Expression of Multiple Immune Checkpoint Proteins.
Zavareh RB; Spangenberg SH; Woods A; Martínez-Peña F; Lairson LL
Cell Chem Biol; 2021 Feb; 28(2):158-168.e5. PubMed ID: 33113406
[TBL] [Abstract][Full Text] [Related]
19. The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints.
Vardhana S; Younes A
Haematologica; 2016 Jul; 101(7):794-802. PubMed ID: 27365459
[TBL] [Abstract][Full Text] [Related]
20. Programmed death-1 ligands PD-L1 and PD-L2 show distinctive and restricted patterns of expression in lymphoma subtypes.
Panjwani PK; Charu V; DeLisser M; Molina-Kirsch H; Natkunam Y; Zhao S
Hum Pathol; 2018 Jan; 71():91-99. PubMed ID: 29122656
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
